Clinical Trial Update: Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization

View source ↗

Summary

This completed clinical trial evaluated the safety and potential efficacy of intravitreal bevacizumab for recalcitrant inflammatory ocular neovascularization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multifocal Serpiginous Choroiditis
• Ocular Toxoplasmosis
• Tuberculosis
• Vogt-koyanagi-harada Syndrome

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Rafic Hariri University Hospital | Conditions: Neovascularization, Tuberculosis | Status: COMPLETED